Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus VANCERIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus VANCERIL.
ARMONAIR RESPICLICK vs VANCERIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine production in the airways.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
2 inhalations (84 mcg) 3-4 times daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life is approximately 2.8 hours in adults; prolonged in patients with hepatic impairment.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily hepatic metabolism; <10% excreted unchanged in urine, <5% in feces.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid